Engineering nanomedicines for improved melanoma therapy: progress and promises D Bei, J Meng, BBC Youan Nanomedicine 5 (9), 1385-1399, 2010 | 149 | 2010 |
Formulation of dacarbazine-loaded cubosomes—part I: influence of formulation variables D Bei, J Marszalek, BBC Youan Aaps PharmScitech 10, 1032-1039, 2009 | 84 | 2009 |
Formulation of dacarbazine-loaded cubosomes. Part III. Physicochemical characterization D Bei, T Zhang, JB Murowchick, BBC Youan AAPS pharmscitech 11, 1243-1249, 2010 | 66 | 2010 |
Enzyme- and Transporter-Mediated Drug Interactions with Small Molecule Tyrosine Kinase Inhibitors J Shao, SJ Markowitz, D Bei, G An Journal of Pharmaceutical Sciences 103 (12), 3810-33, 2014 | 46 | 2014 |
Pharmacokinetics of protocatechuic acid in mouse and its quantification in human plasma using LC–tandem mass spectrometry W Chen, D Wang, L Wang, D Bei, J Wang, WA See, SR Mallery, ... Journal of Chromatography B 908, 39-44, 2012 | 44 | 2012 |
Formulation of dacarbazine-loaded cubosomes—part II: influence of process parameters D Bei, J Marszalek, BBC Youan AAPS PharmSciTech 10, 1040-1047, 2009 | 43 | 2009 |
SAT0226 A first-in-human, study of BMS-986165, a selective, potent, allosteric small molecule inhibitor of tyrosine kinase 2 SR I Catlett, U Aras, Y Liu, D Bei, I Girgis, B Murthy, M Honczarenko Annals of the Rheumatic Diseases 76, 859, 2017 | 33 | 2017 |
First‐in‐human study of deucravacitinib: A selective, potent, allosteric small‐molecule inhibitor of tyrosine kinase 2 IM Catlett, U Aras, L Hansen, Y Liu, D Bei, IG Girgis, B Murthy Clinical and Translational Science 16 (1), 151-164, 2023 | 25 | 2023 |
Pharmacokinetics and tissue distribution of 5,7-dimethoxyflavone in mice following single dose oral administration D Bei, G An Journal of Pharmaceutical and Biomedical Analysis 119, 65-70, 2015 | 20 | 2015 |
Pharmacokinetics and pharmacodynamics of midazolam after intravenous and intramuscular administration in alpacas TK Aarnes, PR Fry, JAE Hubbell, RM Bednarski, P Lerche, W Chen, D Bei, ... American journal of veterinary research 74 (2), 294-299, 2013 | 20 | 2013 |
Benefit-risk assessment of nivolumab 240 mg flat dose relative to 3 mg/kg Q2W regimen in Japanese patients with advanced cancers. HM Bei D, Osawa M, Uemura S, Ohno T, Gobburu J, Roy A Cancer Science 2020 (00), 1-8, 2019 | 11* | 2019 |
Quantification of 5,7-dimethoxyflavone in mouse plasma using liquid chromatography-tandem mass spectrometry (LC-MS/MS) and its application to a pharmacokinetic study D Bei, G An Journal of Chromatography B, 11-17, 2014 | 8 | 2014 |
Quantification of 5,7-Dimethoxyflavone in Mouse Plasma Using Liquid ChromatographyTandem Mass Spectrometry (LC-MS/MS) and Its Application to a Pharmacokinetic Study D Bei, G An AAPS, 2014 | 8 | 2014 |
Determination of chebulagic acid and chebulinic acid and their pharmacokinetics in mouse D Bei, L Xie, K Lu, K Chan, S Basu, Z Liu Cancer Research 73 (8), 2013 | 4 | 2013 |
Benefit-risk assessment of nivolumab 240 mg flat dose relative to 3 mg/kg Q2W regimen in Japanese patients with advanced cancers (vol 111, pg 528, 2020) D Bei, M Osawa, S Uemura, T Ohno, J Gobburu, A Roy, M Hasegawa CANCER SCIENCE 112 (5), 2063-2063, 2021 | | 2021 |
COMPARISON OF PHARMACOKINETICS OF BMS-986165, A TYK2 INHIBITOR, IN JAPANESE AND NON-JAPANESE HEALTHY SUBJECTS. U Aras, D Bei, B He, Y Ishida, L Hansen, B Murthy, Y Liu, IG Girgis CLINICAL PHARMACOLOGY & THERAPEUTICS 103, S58-S58, 2018 | | 2018 |
SAT0226 A first-in-human, study of BMS-986165, a selective, potent, allosteric small molecule inhibitor of tyrosine kinase 2 MB Catlett I, Aras U, Liu Y, Bei D, Girgis I Annals Rheumatic Dis 76, 859, 2017 | | 2017 |
Preparation and characterization of dacarbazine-loaded cubosomes as alternative nanoformulation for melanoma treatment D Bei University of Missouri-Kansas City, 2009 | | 2009 |
Dacarbazine Loaded Cubosome as Potential Nanomedicine for Improved Melanoma Treatment D Bei, J Murowchick, A Endale, BB Youan American Association of Pharmaceutical Scientists, AAPS2008-001296, 2008 | | 2008 |